C. Hermans MD, PhD

O.5 Confirmation of the very low rate of subclinical venous thrombosis in people with hemophilia undergoing major orthopedic surgery in the absence of pharmacological thromboprophylaxis

A-138 DEVELOPMENT OF APPROPRIATE AND CULTURALLY ADAPTED EDUCATIONAL TOOLS ON HAEMOPHILIA FOR THE PATIENTS FROM IVORY COAST AND THEIR FAMILIES

A-103 SYSTEMIC THROMBOLYSIS AND ENDOVASCULAR THROMBECTOMY IN SEVERE ACUTE ISCHEMIC STROKE AFTER DABIGATRAN REVERSAL WITH IDARUCIZUMAB

A-131 SUCCESSFUL AND COST-EFFECTIVE USE OF FC-FUSED FIX DURING MAJOR ORTHOPAEDIC SURGERY

A-106 DABIGATRAN ETEXILATE IN THE TREATMENT OF LOCALIZED INTRAVASCULAR COAGULOPATHY ASSOCIATED WITH VENOUS MALFORMATIONS

Impact of a rare disease on public health today and tomorrow: the case of haemophilia

Summary

Haemophilia is a rare X-linked disease of coagulation, implying a partial or a complete deficiency of circulating factor VIII, in case of haemophilia A, or factor IX, in case of haemophilia B. If untreated, the bleeding tendency in patients with haemophilia may induce spontaneous bleeding episodes leading to serious complications, including premature death. Substitutive treatments consisting of intravenous infusions of clotting factor VIII or IX concentrates, which can be administered in a preventive or curative way, are presently available. To be effective, there is a need to administrate the correct dosing of clotting factors. The optimal substitutive treatment dosing of factor VIII concentrates in haemophilia A is addressed in relation to morphometric variables in the first section of this thesis. However, current treatments for haemophilia have some limitations and the development of new treatments through clinical studies would be beneficial. Factors influencing the motivation of patients to participate in clinical studies to develop new treatments are addressed in the second section of the thesis. Finally, this work was integrated in a general public health perspective by investigating the health and the economic burden of haemophilia in Belgium in the final section. The consumption of coagulation factors needed to treat haemophilia and its associated cost is steadily increasing in Belgium and other developed countries. For the first time the total economic burden of haemophilia in Belgium was estimated. In addition, the disease burden related to haemophilia in Belgium was quantified through Disability-Adjusted Life Year (DALY) calculations.

(BELG J HEMATOL 2016; 7(3):123–6)

P1.15 Multiple Myeloma in Black Africans, clinical and biological characteristics